Abstract
Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Current Pharmaceutical Design
Title: Statins and Solid Organ Transplantation
Volume: 12 Issue: 36
Author(s): I. F. Gazi, E. N. Liberopoulos, V. G. Athyros, M. Elisaf and D. P. Mikhailidis
Affiliation:
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Abstract: Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Export Options
About this article
Cite this article as:
Gazi F. I., Liberopoulos N. E., Athyros G. V., Elisaf M. and Mikhailidis P. D., Statins and Solid Organ Transplantation, Current Pharmaceutical Design 2006; 12 (36) . https://dx.doi.org/10.2174/138161206779026308
DOI https://dx.doi.org/10.2174/138161206779026308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets Mesoionic Oxatriazoles (MOTA): NO-Donating Characteristics and Pharmacology
Current Pharmaceutical Design Random Walks on Biomedical Networks
Current Proteomics Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy SARS: Understanding the Virus and Development of Rational Therapy
Current Molecular Medicine Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Cannabinoids: Occurrence and Medicinal Chemistry
Current Medicinal Chemistry Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Current Diabetes Reviews Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design